Custom Manufacturing, Project Outsourcing, your Trusted Partner from China
The pursuit of more effective cancer treatments often involves exploring synergistic combinations of drugs that target different cellular pathways. This approach leverages the strengths of multiple agents to achieve a greater therapeutic effect than either drug could achieve alone. NINGBO INNO PHARMCHEM CO.,LTD. plays a vital role in enabling such research by supplying essential compounds like AZD2014.
AZD2014, a potent dual inhibitor of mTORC1 and mTORC2, has demonstrated significant therapeutic potential in various cancers. Its mechanism of action involves disrupting key cellular processes such as growth, proliferation, and survival. In the context of hematological malignancies, particularly Diffuse Large B-cell Lymphoma (DLBCL), research has indicated that combining AZD2014 with inhibitors of Bruton's tyrosine kinase (BTK) can lead to dramatic synergistic effects.
BTK is a crucial enzyme in the B-cell receptor signaling pathway, which is often dysregulated in B-cell lymphomas. By inhibiting BTK, these drugs can block signaling that promotes lymphoma cell survival and proliferation. When AZD2014 is introduced alongside a BTK inhibitor, the combined effect appears to be more potent in inducing apoptosis (programmed cell death) in ABC-subtype DLBCL cell lines. This suggests that targeting both the mTOR pathway and the BTK signaling pathway creates a powerful double-hit against these cancer cells.
The significance of this synergy lies in its potential to overcome resistance mechanisms and provide a more effective treatment option for patients with aggressive lymphomas. The ability to purchase AZD2014 for research purposes allows scientists to validate these findings and explore the optimal dosing and combination strategies. Such research is fundamental to developing new treatment protocols that could significantly improve patient outcomes.
NINGBO INNO PHARMCHEM CO.,LTD. is committed to supporting innovative cancer research by providing high-quality chemical reagents. The availability of compounds like AZD2014 empowers researchers to investigate these complex synergistic interactions. As the understanding of cancer biology deepens, the development of targeted combination therapies, informed by compounds supplied by NINGBO INNO PHARMCHEM CO.,LTD., will undoubtedly play an increasingly important role in the fight against cancer.
Manufacturing Facilities
Professional Export Experience
to Global Customers
1. 20 years of R&D, manufacturing and sales experience, serving customers in 60 countries and regions around the world;
2. Own R&D laboratory, pilot platform and large-scale production workshop, which can meet the audit requirements of global customers;
3. We can satisfy customers' perfect transition from small scale lab requirements (gram level) to commercialization requirements (hundred tons level).
A: We don't have Minimum Order Quantity, exact quantity should be provided before quotation for us to calculate the exact cost.
A: We don't provide free samples due to lots of request and expensive international courier's cost, we can deduct the sample charge after commercial order placed.
A: Our payment terms: Small or sample order: T/T IN ADVANCE. Commercial order: First order should be by T/T IN ADVANCE or L/C at sight, and following orders T/T 30~90days is acceptable subject to approval of credit application.
